Detailed Coverage

Dr. Reddy's Laboratories Announces Senior Management and Auditor Appointments

Dr. Reddy's Laboratories has appointed Dr. Sridevi Khambhampaty as the new Global Head of Biologics and a member of its Management Council, effective July 22, 2026. She also joins the company's Senior Management Personnel. Dr. Khambhampaty brings over 20 years of experience in Biologics R&D, Quality, and business leadership, having previously served as CEO of Shilpa Biologics and in senior roles at Syngene International and Intas Biopharma. Her academic background includes a PhD in Biological Sciences and postdoctoral research at Stanford University.

Additionally, the company has appointed M/s Deloitte Haskins & Sells, LLP as its Independent Registered Public Accounting Firm. This firm will audit financial statements for the Annual Report on Form 20-F and review interim statements for Form 6-K filings with the U.S. SEC. This appointment aligns with the firm's existing role as Statutory Auditors appointed on May 12, 2026, for a five-year term under the Companies Act, 2013.

Reader Takeaway: Leadership boost in Biologics vertical; auditor consolidation for US filings.

What just happened

Dr. Reddy's Laboratories announced two significant updates: the appointment of Dr. Sridevi Khambhampaty as Global Head of Biologics and the appointment of Deloitte Haskins & Sells, LLP as its auditor for US SEC filings.

Why this matters

These appointments are crucial for strengthening leadership in a key growth area (Biologics) and ensuring compliance and efficiency in international financial reporting, which can impact investor confidence and operational oversight.

The backstory

Dr. Khambhampaty has a strong track record in the biopharmaceutical industry. Deloitte Haskins & Sells, LLP was already serving as the company's Statutory Auditors.

What changes now

Dr. Khambhampaty will lead the Biologics division, aiming to drive growth. Deloitte will now handle both domestic statutory audits and international SEC filings, streamlining the audit process.

Risks to watch

No immediate risks are apparent from these standard corporate governance and management updates. Focus will be on the execution and performance under the new leadership.

Peer comparison

Appointments of seasoned professionals to lead strategic business units are common across large pharmaceutical companies as they focus on growth and specialized areas like biologics.

Context metrics (time-bound)

Dr. Khambhampaty's appointment is effective July 22, 2026. Deloitte's statutory auditor appointment was on May 12, 2026, for a five-year term. The company now has 15 Senior Management Personnel.